N O R T H C A R O L I N A B I O T E C H N O L O G Y C E N T E R NC Biotechnology Center Your Roadmap for U.S. Expansion: Insights from Deloitte Consulting and Medicago USA Matt Szuhaj, Deloitte Consulting Mike Wanner, Medicago USA Mark Lombard, NC Biotechnology Center
26
Embed
NC Biotechnology Center - Business Review Webinars
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
N O R T H C A R O L I N A B I O T E C H N O L O G Y C E N T E R
NC Biotechnology Center
Your Roadmap for U.S. Expansion: Insights from Deloitte Consulting and Medicago USA
Matt Szuhaj, Deloitte ConsultingMike Wanner, Medicago USA
Mark Lombard, NC Biotechnology Center
Deloitte Consulting LLP
NC Biotechnology Center Webinar – Location Strategy Considerations
Matt Szuhaj
Deloitte Real Estate and Location Strategy Practice
Over 8,000 site selection projects completed since practice founding 1919
Largest site selection consultancy built to advise clients on the most complex location strategy and site selection decisions
A dedicated team of 25+ practitioners focused on global location strategy and site selection
Deep understanding of issues critical to optimal location decisions:– Variable operating costs, conditions, and risks
– Labor market quality & availability
– Logistics/supply chain/infrastructure issues
– Utilities infrastructure and issues
– Real estate and site issues
– Taxes and incentives
Amgen - Asia operations market entry Express Scripts - North American deployment strategy Alcon/ Novartis - European country headquarter location Herbalife - US and EMEA deployment strategy Dendreon - Europe collection center location strategy Johnson & Johnson - China manufacturing strategy Novartis - US manufacturing location strategy Biomarin - Global manufacturing strategy Stryker- Asia manufacturing location strategy
On the ground experience in over 60 countries worldwide
Global Expertise
Deloitte’s Capabilities Sample of Recent Client Engagements
Market Entry Site Selection & Location Strategy
Real Estate & Incentives
On-shoring & Off-shoring
Footprint Optimization
Program Delivery & Management (PMO)
Location Strategy Considerations
Three Key Drivers for Expansion
Talent MarketAccess
Cost
Location Strategy Considerations Across the Life Science Value Chain
– Accessibility of Venture Capital
– Capital Costs– Operating Costs
– Capital Costs– Operating Costs
(taxes and labor)– Incentives
– Operating Costs (taxes and logistics)
– Incentives
R&D Clinical TrialsBulk Manufacturing and
Fill/FinishDistribution
– R&D Presence– Availability of
Resources– Regulatory
Environment– IP Protection & Ease
of Commercialization– Accessibility– Quality of Life
– Availability of Talent– Availability of
Medical Facilities and Networks
– Appropriate Population for Testing
– Regulatory Environment
– Availability of Skilled Labor
– Availability of Support Resources
– Regulatory Environment
– Business Disruption Risk
– Accessibility
– Availability of Labor– Regulatory
Environment– Proximity to
Markets/Customers– Business Disruption
Risk– Quality of Life (cost
of living)
Costs
Conditions
North Carolina Strengths
North Carolina Key Attributes that Affect Location Strategy Decisions
Strengths
Weaknesses
– Skilled labor pool– Quality of Life– Availability of resources/support– Regulatory environment– Utility costs– Capital costs– Labor costs– Cost of living– Accessibility– Business disruption risk– Culture of innovation– Tax environment– Access to venture capital
Key Attributes
Poll Question:
Is your company planning to expand to the United States in the next:
A. 1 yearB. 2 yearsC. 5 yearsD. 10 yearsE. None of the above
Medicago USA• Based in the Research Triangle Park, North Carolina
– 120M doses pandemic or 40M seasonal vaccine per year– 12 months to build - $36M (building + equipment)– 97,000 sq ft facility of which 27,000 is greenhouse– 90,000 plant capacity in the greenhouse– Customized robotics/infiltration equipment– Designed as a multi-product facility
• $21M in funding from US Department of Defense (DARPA)– Goal: produce 10M doses of H1 VLP in one month
US Operations Staff66 total staff • Mike Wanner, VP of US Op Merial, 3 biotech start-ups• Todd Talarico, Sr. Dir of Ind Proc Alphavax• Dave Dumers, Dir of QA Wyeth/Pfizer• Kiyomi Carter, Dir of Project Mgt Biolex, Eli Lilly• Bruno Pancorbo, Ind Process Mgr Alphavax• Joe Sitko, Dir of Engineering Bristol Myers, KBI• Marianne Lorenc, QA Manager Wyeth/Pfizer• David Henry, Dir of Ind Proc Wyeth/Pfizer• Greg Miller, Facility Manager BD Diagnostics, BioMerieux• Charles Bryant- Greenhouse Mgr Athenix (BayerCropScience)• Shay Grogan– Fermentation Spv. Merck (Diosynth)• Dominic Risko – QC supervisor Eisai, Diosynth, Athenix• Jedidiah Leviner, Systems Spt Mgr Avid Solutions• Charlie McElhannon, GH Spv BASF